改善2型糖尿病肥胖患者胰岛素抵抗,减肥手术优于艾塞那肽

2012-04-20 佚名 中国医学论坛报手机报

  中国医科大学附属盛京医院普外科一项研究显示,对于2型糖尿病肥胖患者,胃旁路手术在控制体重和改善胰岛素抵抗等方面均优于艾塞那肽治疗。研究于3月23日在线发表于《肥胖外科学》(Obes Surg)。   研究纳入该院2009年1月~2010年1月接受减肥手术或艾塞那肽治疗的2型糖尿病肥胖患者,收集的数据包括体重改变、血糖、胰岛素变化、HbA1C以及患者的主观评分。结果显示,相比艾塞那肽

  中国医科大学附属盛京医院普外科一项研究显示,对于2型糖尿病肥胖患者,胃旁路手术在控制体重和改善胰岛素抵抗等方面均优于艾塞那肽治疗。研究于3月23日在线发表于《肥胖外科学》(Obes Surg)。

  研究纳入该院2009年1月~2010年1月接受减肥手术或艾塞那肽治疗的2型糖尿病肥胖患者,收集的数据包括体重改变、血糖、胰岛素变化、HbA1C以及患者的主观评分。结果显示,相比艾塞那肽组,减肥手术组体重减轻更明显,血糖改善更佳。治疗6个月时,减肥手术组的餐后胰岛素和HbA1c水平明显低于艾塞那肽组(分别为18.1 mU/L对4.5 mU/L、6.08% 对7.19%,P<0.01),两组患者的脂蛋白、血中各种离子浓度和主观评分等方面均无差异。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950932, encodeId=ccd51950932c5, content=<a href='/topic/show?id=72078190803' target=_blank style='color:#2F92EE;'>#肥胖患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81908, encryptionId=72078190803, topicName=肥胖患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 10 04:13:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749337, encodeId=86271e4933720, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jul 13 01:13:00 CST 2012, time=2012-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393596, encodeId=7d9213935968f, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86756, encryptionId=4a9886e56ed, topicName=艾塞那肽)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950932, encodeId=ccd51950932c5, content=<a href='/topic/show?id=72078190803' target=_blank style='color:#2F92EE;'>#肥胖患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81908, encryptionId=72078190803, topicName=肥胖患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 10 04:13:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749337, encodeId=86271e4933720, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jul 13 01:13:00 CST 2012, time=2012-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393596, encodeId=7d9213935968f, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86756, encryptionId=4a9886e56ed, topicName=艾塞那肽)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-07-13 baoya
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950932, encodeId=ccd51950932c5, content=<a href='/topic/show?id=72078190803' target=_blank style='color:#2F92EE;'>#肥胖患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81908, encryptionId=72078190803, topicName=肥胖患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 10 04:13:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749337, encodeId=86271e4933720, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jul 13 01:13:00 CST 2012, time=2012-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393596, encodeId=7d9213935968f, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86756, encryptionId=4a9886e56ed, topicName=艾塞那肽)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/UdV6ialcayj7Qv8RQm1mVfNYPKxjiaolxwglAZpCo6CwjTicOroW2Xb0Kxnc65viaxGpkuqHW7WzzbYgRLw3qooDoA/132, createdBy=04c22500137, createdName=紫砂壶, createdTime=Sun Apr 22 10:13:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]